TG THERAPEUTICS INC
For the period ended Jun 14, 2024. Filed Jun 17, 2024.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jun 14, 2024 · Filed Jun 17, 2024
Use the contents to explore the available documents and sections.
Contents
Proposal
Proposal 1
The votes with respect to the election of the six directors to hold office until the 2025 annual meeting were as follows:
| Director | Votes For | % Voted For | Votes Withheld | % Voted Withheld | Broker Non- Votes |
|---|---|---|---|---|---|
| Michael S. Weiss | 57,264,472 | 75.23% | 18,849,954 | 24.77% | 34,960,603 |
| Laurence N. Charney | 57,758,626 | 75.88% | 18,355,800 | 24.12% | 34,960,603 |
| Yann Echelard | 35,052,596 | 46.05% | 41,061,830 | 53.95% | 34,960,603 |
| Kenneth Hoberman | 52,058,723 | 68.40% | 24,055,703 | 31.60% | 34,960,603 |
| Daniel Hume | 35,036,823 | 46.03% | 41,077,603 | 53.97% | 34,960,603 |
| Sagar Lonial, MD | 33,299,870 | 43.75% | 42,814,556 | 56.25% | 34,960,603 |
Proposal 2
The vote with respect to the ratification of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was as follows:
| Total Votes For | Total Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|
| 110,028,319 | 657,578 | 389,132 | -- |
Proposal 3
The advisory vote to approve the compensation of the Company’s named executive officers was as follows:
| Total Votes For | Total Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|
| 42,346,581 | 31,019,084 | 2,748,761 | 34,960,603 |
Proposal 4
The vote to approve the amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 175,000,000 to 190,000,000 was as follows:
| Total Votes For | Total Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|
| 73,780,225 | 36,348,764 | 946,040 | -- |
Proposal 5
The vote to approve the amendment to the Company’s 2022 Incentive Plan to remove the full-value awards limit was as follows:
| Total Votes For | Total Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|
| 66,744,142 | 8,625,685 | 744,599 | 34,960,603 |
| Item 9.01. | Financial Statements and Exhibits. |
|---|
(d) Exhibits
| Exhibit No. | Description |
| 3.1 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of TG Therapeutics, Inc. |
| 10.1 | Amendment to the TG Therapeutics, Inc. 2022 Incentive Plan. |
| 104 | Cover Page Interactive Data File (embedded within Inline XBRL document) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.